Gapping up
In reaction to earnings/guidance:
- OSH +34.7% (guidance), ACCD +7.1%, AZZ +4.2%, AMRN +3.4%, WWW +2.8% (guidance), URBN +2.1% (reports record holiday sales)
Other news:
- PRE +83.3% (Prenetics Group's ACT Genomics received FDA clearance for ACTOnco comprehensive genomic profiling test for solid tumors)
- SHC +57.6% (Announces Settlement of Ethylene Oxide Litigation in Illinois; reaffirms guidance)
- FRO +26.1% (terminates Euronav combination agreement)
- MNOV +6.6% (receives a notice of allowance for a new patent covering MN-001 and MN-002 for the treatment of hypertriglyceridemia hypercholesterolemia and hyperlipoproteinemia in Brazil)
- RGNX +4.7% (names new COO)
- SOVO +4.4% (divests its Birch Benders business)
- CANF +4.4% (submits market registration plan to European Medicines Agency for piclidenoson in the treatment of psoriasis; FDA submission to follow)
- TRIN +4.2% (originates $239 mln in gross debt and equity commitments)
- UDMY +3% (CEO and Chairman retiring; names new CEO and interim Chairman)
- CHDN +1.2% (multi-year agreement with bet365)
- RCKT +1.1% (expands cardiac gene therapy portfolio)
Analyst comments:
- AMPS +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- AMT +1% (upgraded to Buy from Neutral at Goldman)